Vitrolife AB
The answer first
Does Vitrolife beat the market?
No, Vitrolife has not beaten the market over the last year.
The ranking · Quality, value and trend combined
Better than 37% of Nordic stocks
- Quality53
- Value14
- Trend69
No. 87 of 195 in healthcare
Expectations in the price
High expectations
For the share to return about 9% a year from today's price, the cash Vitrolife keeps must grow about 11% a year for 10 years.
Max for seven days
Follow Vitrolife with AuroraAurora lets you know at the next report. No card.
Both with dividends. Figures as of 18 November 2026. General analysis, not personal advice.
Follow your thesis
Ask Aurora about Vitrolife
Your first answer is free, no account needed.
Do you own Vitrolife, or are you thinking about it?
See it next to the rest of your portfolio, or build your first one with Vitrolife and a few more. Free, no card.
Super Stock+44.6%In short
- Vitrolife has fallen 14.8% over the past year, including dividends.
- Overall, Vitrolife ranks better than 37% of Nordic stocks on quality, value and trend.
- The largest fall over the past three years was 72.5%. The price is 78.6% below its peak now.
What do analysts think of Vitrolife?
Quality, value and trend
Quality is about the company, value about the price you pay, and trend about the share price. Each pillar shows the numbers it is built on.
Quality, value and trend together. Better than 37% of Nordic stocks.
No. 87 of 195 in healthcare
Medium An average company: the accounts are neither especially strong nor weak.
No. 125 of 196 in healthcareTypical in healthcare: 64Typical in the Nordics: 50
- Debt to equityBorrowings divided by equity0.21
- Asset turnoverSales divided by everything the company owns0.30
- Return on equityProfit divided by equity−61.1%
- Cash conversionOperating cash flow divided by profit–
The ranking is built on equity ratio, ROA and how steadily profit grows.
Low High price: buyers pay a lot today, often because they expect growth.
No. 124 of 197 in healthcareTypical in healthcare: 20Typical in the Nordics: 50
- P/BPrice divided by equity1.9
- P/SPrice divided by sales4.5
- P/EPrice divided by earningsnegative earnings
- P/CFPrice divided by operating cash flow22.3
The ranking is built on P/E, P/B and P/S.
High Tailwind in the share price: it has risen more than most over the last year.
No. 54 of 198 in healthcareTypical in healthcare: 34Typical in the Nordics: 50
- 3 months+29.3%
- 6 months+12.7%
- 9 months+30.7%
- 12 months−14.8%
The ranking is built on 3, 6 and 12–1 months.
Return and risk
Return with dividends reinvested.
The funds that own Vitrolife
27 funds we follow own Vitrolife. The share is how much of the fund the stock makes up.
- Norway2
- Sweden24
- Denmark1
- 1 ETF
- PLUS Hälsovård Sverige IndexSweden · PLUS3.4%
- Cliens Small & Micro Cap ASweden · Cliens1.5%
- Wealth Inv I&T Nord AktLargeCaDenmark · Wealth Invest1.3%
- Skandia Småbolag SverigeSweden · Skandia0.9%
- Vibrand Norden ANorway · Vibrand0.9%
- Öhman Småbolagsfond ASweden · Öhman0.6%
- Öhman Sweden Micro Cap ASweden · Öhman0.6%
- Lysa Sverige Aktier BSweden · Lysa0.5%
Show all 27
- SEB Europafond SmåbolagSweden · SEB0.5%
- Handelsbanken Nordiska Småbol (A1 NOK)Sweden · Handelsbanken0.5%
- PLUS Småbolag Sverige IndexSweden · PLUS0.3%
- Xact Svenska Småbolag (UCITS ETF)Sweden · XACT · ETF0.3%
- Skandia Småbolag Sverige Exponering ASweden · Skandia0.2%
- Handelsbanken Norden Ind Crit (A1 NOK)Sweden · Handelsbanken0.2%
- Avanza Sweden All Cap ASweden · Avanza0.1%
- Skandia Sverige ExponeringSweden · Skandia0.1%
- Case All StarSweden · Case0.1%
- Öhman Etisk Index Sverige ASweden · Öhman0.1%
- PLUS Allabolag Sverige IndexSweden · PLUS0.1%
- KLP AksjeNorden IndeksNorway · KLP0.0%
- GodFond Sverige & VärldenSweden · GodFond0.0%
- SPP Aktiefond Sverige ASweden · SPP0.0%
- Handelsbanken Gl Småbolag I Crit A9 EURSweden · Handelsbanken0.0%
- Handelsbanken Gl Småbolag Ind Cri A1 NOKSweden · Handelsbanken0.0%
- Nordea Avtalspensionsfond MidiSweden · Nordea0.0%
- Skandia SMART FörsiktigSweden · Skandia0.0%
- Skandia Världen SverigeSweden · Skandia0.0%
From the funds' latest known holdings.
About Vitrolife
Vitrolife AB is a company in healthcare, listed on Nasdaq Stockholm. The share trades in SEK. It has around 1,100 employees.
Vitrolife AB (publ) provides assisted reproduction products in Europe, the Middle East, Africa, Asia-Pacific, and the Americas. It offers sperm processing, oocyte retrieval needles, micromanipulation pipettes, time-lapse systems, and evaluation tools, laser and imaging systems, IVF media and oil, embryo transfer, cryopreservation, and genomics kits. The company also provides eWitness and Labware products, such as dishes, pipettes, tubes, and VitroTemp. The company was incorporated in 1989 and is based in Gothenburg, Sweden.


See the full analysis of Vitrolife.
The accounts, dividends, 40 years of charts and the comparison with other stocks are in the app.
Free forever · No card